Browse KCP

Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF00093 von Willebrand factor type C domain
PF00094 von Willebrand factor type D domain
Function

Enhances bone morphogenetic protein (BMP) signaling in a paracrine manner. In contrast, it inhibits both the activin-A and TGFB1-mediated signaling pathways (By similarity).

> Gene Ontology
 
Biological Process GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0030509 BMP signaling pathway
GO:0030510 regulation of BMP signaling pathway
GO:0030513 positive regulation of BMP signaling pathway
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KCP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KCP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KCP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2610.487
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2430.7
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6310.232
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91601
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 5901
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 4701
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3150.549
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3480.664
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1730.833
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.7720.408
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5080.675
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5890.00495
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KCP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.212.59.70.602
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KCP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KCP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KCP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KCP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KCP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KCP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKCP
Namekielin/chordin-like protein
Aliases FLJ33365; NET67; kielin; CRIM2; cysteine rich BMP regulator 2 (chordin-like); CRIM21; CRIM-2; cysteine-rich ......
Chromosomal Location7q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KCP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.